KDNY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KDNY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Chinook Therapeutics has the Financial Strength Rank of 6.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.GuruFocus does not calculate Chinook Therapeutics's interest coverage with the available data. Chinook Therapeutics's debt to revenue ratio for the quarter that ended in Jun. 2023 was 8.43. As of today, Chinook Therapeutics's Altman Z-Score is 10.65.
For the Biotechnology subindustry, Chinook Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Chinook Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Chinook Therapeutics's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Chinook Therapeutics's Interest Expense for the months ended in Jun. 2023 was $0.00 Mil. Its Operating Income for the months ended in Jun. 2023 was $-70.38 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $29.72 Mil.
Chinook Therapeutics's Interest Coverage for the quarter that ended in Jun. 2023 is
GuruFocus does not calculate Chinook Therapeutics's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Chinook Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
Chinook Therapeutics's Debt to Revenue Ratio for the quarter that ended in Jun. 2023 is
Debt to Revenue Ratio | = | Total Debt (Q: Jun. 2023 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (4.268 | + | 29.717) | / | 4.032 | |
= | 8.43 |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Chinook Therapeutics has a Z-score of 10.65, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 10.65 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chinook Therapeutics (NAS:KDNY) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Chinook Therapeutics has the Financial Strength Rank of 6.
Thank you for viewing the detailed overview of Chinook Therapeutics's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew James King | officer: Head of Renal Discovery | C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102 |
William Mariner Greenman | director | C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520 |
Eric Dobmeier | director, officer: President, CEO | C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021 |
Davis Jerel | director, 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Robert Azelby | director | 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109 |
Mahesh Krishnan | director | 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Andrew Oxtoby | officer: Chief Commercial Officer | 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005 |
Tom Frohlich | officer: Chief Business Officer | C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102 |
Eric Bjerkholt | officer: Chief Financial Officer | 132 PURDURE AVENUE, KENGSINGTON CA 94708 |
Dolca Thomas | director | C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Srinivas Akkaraju | director | 565 EVERETT AVENUE, PALO ALTO CA 94301 |
Alan Glicklich | officer: Chief Medical Officer | C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102 |
Versant Voyageurs I, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Voyageurs I Parallel, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Venture Capital Vii, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
From GuruFocus
By Marketwired • 07-28-2023
By Business Wire • 07-21-2023
By PRNewswire • 07-17-2023
By sperokesalga sperokesalga • 06-12-2023
By ACCESSWIRE ACCESSWIRE • 06-20-2023
By PRNewswire • 07-17-2023
By ACCESSWIRE • 06-29-2023
By Marketwired • 06-22-2023
By Marketwired • 07-21-2023
By PRNewswire PRNewswire • 06-12-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.